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In 1939 a red protein was discovered in bovine milk by Sorensen and 
Sorensen. This protein has been given various names, such as lactoferrin, 
lactotransferrin, lactosiderophilin or red milk protein. 
Because of its absence in serum, lactoferrin has been regarded as a 
specific milk protein. However, by using inmunological methods it has also 
been possible to demonstrate the presence of lactoferrin in various external 
fluids. Elevations in the level of lactoferrin in secretions have been re-
ported in several infectious diseases, such as mastitis, pancreatitis and 
salivary gland diseases. Therefore, lactoferrin might play an important 
role in protection of epithelial tissues from infection. 
The presence of lactoferrin in saliva suggests that it may be important 
in the control of oral disease processes, such as gingivitis, periodontitis 
and dental caries. 
The purpose of this study was to detennine if there is any differences 
in the concentrations of lactoferrin in saliva between patients with gingi-
vitis and clinically healthy individuals without gingivitis, using the enzyme-
linked inmuno-sorbent assay (ELISA} technique. Changes in the level of lac-




REVIEW OF LITERATURE 
Iron and Infection 
Iron is required by all living cells, including bacteria. According 
to Weinberg (1978), bacteria need approximately 0.4 to 4.0 uM iron for growth. 
In the context of bacterial growth in man iron not freely available to micro-
organisms. Iron content of an average man is 4.5 gm (Bell et al., 1953). It 
is tightly bound to hemoglobin, myoglobin, ferritin and hemosiderin. Although 
the total iron concentration in manmalian body fluids is 2 x 10-5M (Grif-
fiths et al., 1980), almost all of the iron is associated with iron-binding 
and transport proteins such as transferrin in plasma and lactoferrin in mu-
cosal secretions. Only 10-18M free-iron is available in body fluids (Bullen 
et al, 1978; Bullen et al, 1981). This concentration is far lower than the 
bacteria need for growth. Furthermore, mammals, birds, reptiles and verte-
brates can make metabolic adjustment during infection to withhold the essen-
tial iron from invading bacteria. Such invaded hosts promptly become hypo-
ferrimic by halting intestinal assimilation and by increasing the quantity 
in storage of iron in the liver (Weinberg, 1974). 
Prior stationing of host iron-binding proteins at potential sites of 
bacterial invasion and increased synthesis of host iron-binding proteins are 
also two possible antibacterial protective mechanisms (Weinberg, 1978). The 
ability of the host to withhold iron from microbes is called "nutritional 
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immunity". The term was first used by. Kochan in 1973. Therefore, it is the 
ability of the microbes to acquire the iron essential for their growth and 
metabolism that may determine the nature of the host-parasite interactions. 
One strategy to obtain iron by the successful pathogens is that they must 
rapidly adapt to the low-iron environment. The successful pathogens produce 
powerful iron-chelating agents that can remove iron from iron-binding pro-
teins. Because of extreme insolubility of ferric ion at neutral pH, aerobic 
and facultative microbes can synthesize either phenolates, which are deriva-
tives of 2,3-dihydroxybenzoic acid, or hydroxamates, which are derived from 
hydroxamic acid. Phenolates and hydroxamates in bacteria serve to solubilize 
and assimilate the iron. These compounds are known as 11 siderophores 11 • Anaero-
bic bacteria do not need to produce such iron-binding compounds, as they pro-
duce transport ligands that have a selective affinity for ferrous ion (Lank-
ford, 1973}. 
Many studies on experimental infection have shown that iron enhances 
bacterial virulence (Weinberg, 1978; Bullen, 1981; Findelstein et al., 1983; 
Hill, 1978; Bullen et al., 1968} in such strains as Pseudomonas aeruginosa, 
Escherichia coli, Vibrio cholerae, Neisseria meningitidis, Neisseria gonor-
rhoeae, Bacteroides melaninogenicus and Staphylococcus aereus. 
Bornside et al. (1968) have shown that both£. coli and hemoglobin are 
necessary to produce lethal effect in infections of the peritoneal cavity. 
Although f. coli is a common inhabitant of the gut, it usually is not regrad-
ed as a highly virulent pathogen. They also found that lysed red cells were 
as effective as hemoglobin with I· coli in producing a lethal effect. 
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Bullen et al. (1968) further demonstrated that it is the iron in hemo-
globin that is responsible for stimulating bacterial growth. They reported 
that 1· coli possess a binding site for the iron binding heme molecule from 
which it gains selective growth advantage, when hemoglobin is available. 
Based upon a number of clinical studies there is evidence of a correl-
ation between the increase in the hemoglobin concentration in serum and sus-
ceptibility to infection. Bullen (1981) concluded that it is the liberation 
of heme compounds that can enhance clinical infections. 
Gingival bleeding commonly accompanies gingivitis and periodontitis. 
In such diseases the excess hemoglobin that was released could enhance the 
virulence of the bacteria in the gingival sulcus. 
Buhler and Muhlemann (1975) recorded the degree of gingivitis and col-
lected the stimulated mixed saliva from 50 subjects, before and after a 10-
day period of intensified oral hygiene and measured the iron content in the 
saliva. They found that the use of methods to improve oral hygiene can re-
duce gingival inflammation and salivary iron content. Gingival inflammation 
was significantly but not strongly (r= 0.51) correlated with salivary iron 
content. 
Mukherjee (1985) measured the concentration of iron in crevicular fluid 
from sites in gingivitis and periodontitis in human subjects. The results 
showed that the concentrations of iron in crevicular fluid collected from 
periodontitis sites were significantly higher than those collected from 
gingivitis sites (5.196 vs. 3.042 mg/L). These concentrations (5.196 and 
3.042 mg/L) were higher than the concentration in serum (about 1.26 mg/L) as 
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reported by Skypeck and Joseph (1981). Mukherjee concluded that this high 
iron concentration in crevicular fluid might play an important role in the 
growth and virulence of microorganisms of subgingival plaque and the initia-
tion of active periodontitis. 
Becraft et al. (1977) performed in vitro studies to investigate the 
relationship between the administration of intramuscular iron-dextran for 
prevention of iron deficiency and the susceptibility to I· coli infection. 
They found that an increased incidence of.£_. coli meningitis occurred after 
iron-dextran treatment. They reported in these cases the sepsis was due 
to excess iron concentration in serum. Excess iron causes inhibitory ef-
fects on leukocytes chemotaxis and markedly reduced bacteriostatic effects 
against.£_. coli. 
Bullen and Wallis (1977) also have demonstrated that such reversal of 
the bactericidal effect of polymorphonuclear leukocytes occurs by a fer-
ritin-antibody complex. They found that there is no effect on abolishing 
the bactericidal power of polymorphonuclear leukocytes by exposing them to 
iron salts unless high concentrations of iron are used. They further re-
ported that if the iron is presented in the form of a ferritin-antibody 
complex it is readily phagocytosed by neutrophils, and that the introduction 
of iron in this form, results in a viable bacterial count 346 times that of 
the controls at 8 hours. 
Sources of Lactoferrin 
Lactoferrin was first described in bovine milk by Sorensen and Soren-
sen in 1939. Johansson in 1958 found the similar iron-binding protein in 
human milk. Montreuil et al. in 1960 described a method of isolating and 
pruifying lactoferrin from human milk. 
Biserte et al. in 1963 first demonstrated lactoferrin in sputum and 
could not identify it in saliva. They considered lactoferrin to be bron-
chial origin. 
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Using i11111unohistochemical method by staining sections of biopsy spe-
cimens with fluorescein-labelled antiserum against lactoferrin, Masson et 
al. (1965, 1966) further demonstrated the presence of lactoferrin in all 
bronchial glands. Both serous and mucous cells appeared to be involved in 
the production of lactoferrin. 
Masson et al. (1965b) reported the same iron-binding protein in human 
saliva. A bronchial origin for the salivary lactoferrin is not at all im-
possible, since bronchial mucus is known to reach the pharynx owing to the 
propulsory activity of the ciliated respiratory epithelium. However, Masson 
et al. (1966) have obtained further invnunohistochemical evidence for the 
occurrence of lactoferrin in the salivary glands. 
Masson et al (1966, 1966b) demonstrated that lactoferrin is present 
in a large number of human secretions: (1) respiratory secretions, e.g. 
nasal and bronchial fluids; (2) tears; (3) secretions from the glandular 
appendages of the digestive tract, e.g. saliva, bile and pancreatic juice; 
(4) genital secretions, e.g. seminal fluid and cervical mucus and (5) urine. 
The inmunohistological localization of lactoferrin in the mucosa of a 
variety of normal human tissues was investigated using specific fluores-
. 
ceinated antisera by Tourville et al. (1969). They found that the lacto-
ferrin was much less ubiquitous in the epithelial cells of the various 
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tissues studied and appeared to be restricted pri~arily to the acinar ep-
ithelium of the bronchial mucosa, parotid and submaxillary salivary glands 
(serous acinar cells only}; and was also found in renal tubular cells. 
Reitano et al. (1980} used an i11111unoperoxidase technique to study the 
distribution of lactoferrin in human salivary glands from autopsy tissues. 
Such tissues were fixed in Carnoy's fluid for the optimal preservation of 
lactoferrin antigenicity. They found that specific staining was seen in 
the intralobular ducts of all salivary glands but never in the interlobular 
ducts. Also, acinar lactoferrin was detected in most serous demilunes of 
the mixed glands and in some, but not all, acinar cells of the pure serous 
glands. However, no lactoferrin was detected in the acinar cells of the 
pure mucous glands. They also found that polymorphonuclear leukocytes were 
the only additional cells containing lactoferrin in the oral tissues studied. 
Moro et al. (1984} used an inmunofluorescence technique to examine the 
distribution of lactoferrin in human minor salivary glands. Lactoferrin was 
found in serous acini, demilunes, intercalated and intralobular ducts. They 
concluded that in addition to major salivary glands and gingival crevicular 
fluid, the minor salivary glands are also sources of lactoferrin in whole 
saliva. The reported findings cited above have created the impression that 
lactoferrin is chiefly an epithelial secretion product. 
Masson et al. (1968} studied the human uterine cervix and found that 
lactoferrin originated from a particular cell type adjacent to the epithe-
1 ium, possibly white cells. Also, their investigations on guinea pig tis-
sues have shown that the spleen and bone marrow also are rich sources of 
lactoferrin. They concluded that glandular epithelia are not the only 
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sources of lactoferrin in mucosal and external secretions, but certain blood 
cells may also be implicated in the production of this protein. 
Masson et al. (1969) have demonstrated that lactoferrin is one of the 
major proteins present in human and guinea pig neutrophilic polymorphonu-
clear leukocytes. This identification was based on a comparison of its 
electrophoretic, antigenic, and iron-binding properties with the correspond-
ing properties of the same protein isolated from human and guinea pig milk. 
Immunochemical quantitations showed that lactoferrin occurs in human neutro-
phil ic leukocytes at the concentration of 3 ug per 106 cells. Immunohisto-
chemical data indicated that lactoferrin first appears in myeloid cells at 
the stage of the promyelocyte. 
Baggiolini et al. (1970) further demonstrated that the lactoferrin of 
rabbit heterophil leukocytes has an intracellular distribution almost identi-
cal to that of alkaline phosphatase. The parallelism between lactoferrin 
and alkaline phosphatase was observed both in the sedimentation rate and in 
equilibrium density. They concluded that lactoferrin in the heterophil 
leukocytes belongs to the same granules as does alkaline phosphatase. They 
are specific (secondary) granules in polymorphonuclear leukocytes. 
Using direct and indirect immunofluorescent staining, Green et al. 
(1971) found that lactoferrin was located in the nuclei and/or nuclear mem-
brane of mature human polymorphonuclear neutrophilic leukocytes. However, 
it is absent from lymphocytes, monocytes and eosinophiles. While Masson 
et al. (1969) have reported that lactoferrin was located in the cytoplasm 
of human polymorphonuclear leukocytes. Green et al. explained the discrep-
ancy in the localization of lactoferrin in the nucleus and cytoplasm could 
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be due to using different fixative and lactoferrin from different species. 
Leffell and Spitznagel (1972) also found that lactoferrin is contained 
in cytoplasmic granules of human polymorphonuclear leukocytes. Upon centri-
fugation, it sediments in a band of granules that also contain 50% of the 
lysozyme activity. Their findings accorded with those of Masson et al. and 
Baggiolini et al. (1970). 
Properties of Lactoferrin 
Lactoferrin has a single-chain.structure with the molecular weight 
75,000 - 80,000 (Querinjean et al. 1971; Castellino et al., 1970). Each 
molecule has two specific metal-binding sites. One bicarbonate ion will 
bind tightly for each metal ion complexed to the protein (Masson and Heremans, 
1968b). Teuwissen et al. (1972) by means of a spectrophotometric titration 
method, found that the binding of Fe3+ by apolactoferrin or apotransferrin 
involves three tyrosyl residues per metal ion. 
Gordon et al. (1963) had determined the amino acid composition of 
lactoferrin in bovine milk, and found that the basic character of the pro-
tein is evidenced by an excess per molecule of 27 cationic residues over 
anionic residues. Some investigators have insisted on the resemblance be-
tween lactoferrin and the iron-binding protein from serum, transferrin, be-
cause both proteins have a single-chain structure with the same molecular 
weight (Querinjean, 1971). They also have the same metal-chelating proper-
ties, as both are able to bind two atoms of iron. For each Fe3+ taken up, 
one moleucle of bicarbonate is incorporated (Masson and Heremans, 1968b) and 
three protons are released (Querinjean, 1971). However, the two proteins 
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appear to differ widely from one another, since no immunologic cross-reac-
tivity has been demonstrated between serum transferrin and lactoferrin of 
the same species (Montrenil et al., 1960; Blanc and Isliker, 1961). Amino 
acid compositions have also failed to show similarities (Gordon et al., 
1963; Blanc et al., 1963). Furthermore, the iron-binding sites of lacto-
ferrin are more stable at pH values below 4.0 than those of transferrin 
(Johansson, 1960). Aisen and Leibman (1972) had shown that the binding con-
stant for iron at pH 6.4 - 6.7, was 300 times larger for lactoferrin than 
for transferrin. 
The Function of Lactoferrin 
It has been reported by Schade (1946) that iron-free serum transferrin 
displays marked bacteriostatic effect on microorganisms. In order to assess 
whether lactoferrin has the similar properties, Masson et al. (1966b) per-
formed a number of experiments in which solutions of lactoferrin of various 
degrees of saturation with iron were tested for their inhibiting capacity. 
They found a clear inhibitory effect by unsaturated lactoferrin on the Staph-
ylococcus albus, Staphylococcus aureus and Pseudomonas aeruginosa. This in-
hibitory activity had disappeared when ferrous ammonium sulfate had been 
added to the lactoferrin. They suggested that iron-unsaturated lactoferrin 
is bacteriostatic in action. 
Reiten and Oram (1967) found that lactoferrin is very heat stable 
(90°C for 60 minutes) but is inactivated by trypsin. They also reported 
that purified lactoferrin inhibited the growth of Bacillus stearothermophilus 
and Bacillus subtilis and that its inhibitory activity is suppressed by 
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ferrous ions. 
Oram and Reiter (1968) further extended their study and again have 
shown that the bacteriostatic action of lactoferrin was suppressed by Fe2+ 
2+ 2+ .2+ 2+ 
and enhanced by Zn ·' Co , N1 , and Cu . 
Similar findings were reported by Kirkpatrick et al. (1971), by using 
radial i11111unodiffusion method to measure the content of lactoferrin in par-
otid flui.ds and leukocytes from patients with chronic mucocutaneous candi-
diasis and normal subjects. They found that there were no differences in 
the concentrations of lactoferrin in the salivas from two groups. The iron-
unsaturated protein markedly impaired replication of the yeast, and the 
growth-inhibitory property was lost when lactoferrin was saturated with 
iron. 
Bullen et al. (1972) found that human milk with unsaturated iron-bind-
ing lactoferrin had a powerful bacteriostatic effect on Escherichia coli. 
The bacteriostatic properties of milk were abolished if the iron-binding 
proteins were saturated with iron. They also studied guinea pig milk, and 
found that newly born guinea pigs fed on an artificial diet and dosed with 
E. coli had higher counts of E. coli in the intestine than normally suckled 
animals. They suggested that iron-binding proteins in milk may play an 
important role in resistance to infantile enteritis caused by E. coli. 
Reiter et al. {1975) found two strains of E. coli that were not in-
hibited by undiluted colostral whey or milk. However, the colostral whey 
became bacteriostatic for E. coli after dialysis or dilution in Kolmer 
saline and the addition of precolostral calf serum or lactoferrin. The 
lack of inhibition of E. coli in undiluted whey is due to the high 
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concentration of citrate in colostral whey and milk. It is suggested that 
citrate competes with the iron-binding proteins for iron and makes the 
citrate-iron complex available to the bacteria for growth. 
Bishop et al. (1976) reported in their in vitro study that as little 
as 0.02 mg of apo-lactoferrin per ml deionized distilled water in marked 
inhibition of all mastitis-causing coliform bacteria. Growth inhibition was 
lost if iron-saturated lactoferrin or iron plus apo-lactoferrin was added to 
the synthetic medium. They also found that apo-lactoferrin at 20 mg/ml was 
bactericidal for E.coli. The addition of apo-lactoferrin plus citrate re-
sulted in loss of growth inhibition, however, the molar ratio (citrate to 
apo-lactoferrin) was found to be more important than the absolute concentra-
tion of either component. Because a ratio of 75 resulted in 50% growth in-
hibition of E.coli, whereas ratios of 300 and greater resulted in less than 
10% growth inhibition. 
The antimicrobial action of lactoferrin has been attributed to the 
ability of depriving the essential iron. And the reversibility of this an-
timicrobial effect, when an excess of iron is supplied to the nutritionally 
deprived organisms, suggests a simple bacteriostatic effect for lactoferrin. 
But Arnold et al. (1977) showed Streptococcus mutans and Vibrio cholerae, 
but not Escherichia coli, were killed by incubation with purified human lac-
toferrin. The resistance of E. coli to the bactericidal action of lacto-
ferrin in their study, could be due to the production of iron chelators 
(enterochelins). The ability to synthesize iron chelators has been sug-
gested as a significant virulence factor for several enteropathogenic strains 
of E. coli. The investigation by Bullen et al. (1972) and Bishop et al. 
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(1976) have suggested that synthesis of enterochelins allows the bacteria 
to utilize lactoferrin. 
Bullen and Annstrong (1979) reported rabbit polymorphonuclear leuko-
cytes contain the iron-binding protein lactoferrin and can rapidly phago-
cytose and destroy Pseudomonas aeruginosa. If the cells are exposed to a 
ferritin-antibody complex, large amounts of this are phagocytosed by poly-
morphonuclear leukocytes and appear in the cytoplasmic granules and phago-
somes. This leads to saturation of the cellular iron-binding protein with 
Fe, the bactericidal power of the cells is greatly reduced with the result 
that some phagocytosed bacteria survive and eventually grow and destroy 
the cells. An apoferritin-antibody complex used as a control is also phag-
ocytosed by polymorphonuclear leukodytes but has no effect on the bacteri-
cidal power of the cell. 
Arnold et al.(1980) extended their study on bactericidal activity of 
human lactoferrin. The sensitivity of a variety of miroorganisms to human 
lactoferrin was investigated. Some of the microorganisms were clinical 
isolates from 4-day supragingival plaque samples. They found that suscep-
tible microorganisms includes Gram-positive and Gram-negative microbes, rods 
and cocci, facultative anaerobes, and aerotolerant anaerobes. Also, they 
found organisms of the same species and even of the same strain can differ 
in susceptibility to lactoferrin. They suggested that accessibility of the 
microorganisms to the lactoferrin target site may account for differences 
in susceptibility. 
Arnold et al. (1981) studied the influence of the metabolic state of 
the bacteria, the incubation temperature, pH, and the presence of metal 
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ions on the kinetics of killing Streptococcus mutans by lactoferrin. They 
found that after exposure to lactoferrin, a 15-minutes lag period occurred 
before the initiation of killing, indicating that a two step process i~ in-
volved in lactoferrin killing. Cultures harvested during the early exponen-
tial phase were very sensitive to lactoferrin, whereas cultures harvested in 
the early stationary phase were markedly more resistant. Also, the rate of 
killing was dependent on temperature. At 37°C, there were no detectable 
colony-forming units (CFU) after 1 hour of incubation. However, when the 
incubations were carried out at 23°C or at 4°C, the rate of killing was 
markedly reduced. Additionally, bactericidal activity was enhanced under 
the slightly acid environment. This indicated that the reduction of the 
killing activity at neutral pH and the loss of killing under slightly alka-
line condition might be due to the significant conformational changes of 
lactoferrin that occur with increasing pH. Furthermore, exogenous ferrous 
or ferric ions did not reverse or prevent lactoferrin killing. 
Arnold et al. (1982) compared the bactericidal effects of lactoferrin 
on Streptococcus mutans with the bacteriostatic effects on iron deprivation. 
They found that growth and macromolecular synthesis (DNA, RNA and protein) 
were inhibited by incubation of S. mutans with purified human lactoferrin. 
Their early studies (1980, 1981) have shown that lactoferrin binds to the 
surface of susceptible bacteria, and this binding could result in the in-
hibition of growth by blocking some essential transport sites, resulting in 
nutritional deprivation of the bacteria. If this is true, then removal of 
the surface-bound lactoferrin should reverse this inhibition. But, in the 
experiments (1982}, even after using a variety of washing agents to remove 
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the bound lactoferrin from the cell surface, the viability could not be re-
stored. They concluded that this inhibition of metabolism and rapid loss 
in viability observed with lactoferrin treatment suggest that lactoferrin 
has a direct bactericidal effect on S. mutans that can not be attributed to 
simple iron deprivation. An alternative possible suggestion was that the 
binding of lactoferrin to the bacterial cell surface triggers a second pro-
cess that results in the irreversible cell death. 
Oseas et al. (1981) found that PMNs released the specifi~ granule pro-
duct lactoferrin more rapidly in response to chemotatic stimuli, which cor-
related with promotion of PMNs aggregation and enhanced PMNs adherence. 
They suggested that PMN lactoferrin serves an autoregulatory role to retain 
PMNs at inflanmatory sites to amplify the inflanmatory response. 
Ambruso and Johnston (1981) reported that iron-saturated lactoferrin 
from human colostrum and human neutrophils enhances the generation of the 
bactericidal hydroxyl radical. This product may result from the competetive 
ability of lactoferrin to obtain iron from bacteria. They suggested that 
in addition to antimicrobial function, lactoferrin could play an important 
role as regulator of hydroxyl radical production during phagocytosis. 
Alteration of Lactoferrin Levels 
Estevenon et al. (1975) used an inmunodiffusion technique to test the 
presence of lactoferrin in the duodenal juice of patients with chronic cal-
cifying pancreatitis (CCP). They found that almost all patients with CCP 
and 7% of control subjects without CCP have shown lactoferrin in duodenal 
juice. They suggested that the lactoferrin test could have a certain value 
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in the diagnosis of CCP, especially in the differential diagnosis between 
CCP and other pancreatic diseases. 
Colomb et al. (1976) further extended their study in 1975. By using 
the i1T1Tiunodiffusion techniques, lactoferrin was present in the pathological 
pancreatic juice only. However, when indirect ilTITlunofluorescence method was 
used, the fluorescence was found in all samples, including normal pancreatic 
tissue. The difference between these two techniques were explained by the 
different sensitivity and these results indicated that lactoferrin is a pro-
tein of pancreatic secretions. 
Fedail et al. (1978) used radioimmunoassay to measure the concentra-
tion of lactoferrin in pure pancreatic juice from the patients with chronic 
pancreatitis and control subjects. They found that mean concentrations of 
lactoferrin were 2310 mg/ml (range 870 - 11,4000) in the patients with chron-
ic pancreatitis and 128 mg/ml (range 30 - 390) in control subjects. They 
suggested that the measurement of lactoferrin concentration in pure pan-
creatic juice may be useful in the diagnosis of pancreatic diseases. Lacto-
ferrin seems is a sensitive marker of chronic pancreatitis because lacto-
ferrin concentrations in pancreatic juice are specifically elevated in these 
patients. 
Harmon et al. (1975) determined the lactoferrin concentration in milk 
by electroimmunodiffusion assay from normal lactating cows and cows with 
mastitis. They found that the mean concentration of lactoferrin in normal 
group was 0.35 mg/ml. In contrast, that found in the mastitis group from 
0.55 mg/ml on day 1 to 1.89 mg/ml by day 3. Harmon et al. (1976) also found 
that experimentally induced Escherichia coli infection of bovine marrmary 
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gland resulted in a 30-fold increase in lactoferrin concentration in mammary 
secretion by_90 hours post-inoculation, and 4-fold increase in total daily 
production of lactoferrin by 264 hours post-inoculation. They suggested 
that the increased lactoferrin production may be a result of a specific re-
sponse of secretory tissue to inflammatory agents. 
Tabak et al. (1978, 1978b) examined the levels of lactoferrin in the 
parotid secretions of groups of patients (a) with chronic recurrent paro-
titis, (b) with complaints of dry mouth but no evidence of disease, (c) with 
suspected or confirmed Sjogren's disease, (d) with sarcoidosis and (e) with 
diabetes. They found that lactoferrin values in parotid saliva during the 
active phase of parotitis were elevated from two to twenty times normal. 
The values for the recovery phase of parotitis were lower than in the active 
phase, but still two to ten times normal. Elevations in lactoferrin were 
also noted in five of six patients with Sjogren's disease, but not in sub-
jects with sarcoidosis, diabetes or "dry mouth" without sialographic changes. 
In 1971, Kakizaki et al. reported a direct relationship between ex-
perimentally induced pancreatic disorders and alterations of histology and 
function of the parotid glands. Later, they developed a new test on parotid 
saliva and emphasized the usefulness of the saliva test for the diagnosis of 
pancreatic diseases (Kakizaki et al., 1976). 
In order to find out if lactoferrin levels in parotid saliva are ele-
vated in chronic pancreatitis, Durr et al. (1982) and Benini et al.· (1983) 
measured the concentration of lactoferrin in parotid saliva from patients 
with pancreatitis and controls. They found that there was no difference in 
the lactoferrin between these two groups. They concluded that the elevation 
of lactoferrin concentration is confined to the exocrine pancreas and do 
not affect salivary glands in chronic pancreatitis. 
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Fridman et al. (1983) using rocket immunoelectrophoresis to study the 
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concentrations of lactoferrin and lysozyme in the crevicular fluid from 
patients with gingivitis, adult periodontitis, localized juvenile periodon-
titis and normals. They found that lactoferrin in the normal group was sig-
nificantly lower than those in gingivitis group (0.63 vs. 1.5 ug/ul) but did 
not show significant differences between gingivitis, adult periodontitis 
and localized juvenile periodontitis. 
Konttinen et al. (1984) studied the concentration of salivary lacto-
ferrin in patients with Sjogren's syndrome by radioinvnunoassay. The concen-
tration of lactoferrin in unstimulated mixed saliva in Sjogren's syndrome 
group was 16.28 ± 3.05 ug/mg of protein (range 7.42 - 33.64) and that in sex 
and age matched normal group was 2.82 ± 0.82 ug/mg of protein (range 0.59 -
7.35). They demonstrated that by using the peroxidase-antiperoxidase stain-
ing method for labial salivary gland biopsy, a strong staining of lactofer-
rin was found in intralobular and interlobular ducts. Their results indi-
cated that the concentration of unstimulated, mixed salivary lactoferrin is 
a useful diagnostic tool for the diagnosis of Sjogren's syndrome. They sug-
gested that abnormal salivary duct secretion and/or reabsorption is the 
reason for high salivary lactoferrin values. 
Muratsu and Morioka (1985), in order to study the mechanisms of in-
creased susceptibility to oral infection in diabetics, examined the level 
of salivary antibacterial factors; including lysozyme, lactoperoxidase and 
and lactoferrin in diabetic hamsters. They found that although lysozyme 
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activity decreased by 56% and lactoperoxidase activity decreased by 53% in 
diabetic hamsters, there was no significant difference between the strepto-
zotocin induced diabetic and non-diabetic hamsters in the amount of salivary 
lactoferrin. Also, before insulin treatment the ratio of lactoferrin to 
total protein increased to double the amount of that of the control hamsters. 
After the insulin treatment, the ratio of lactoferrin to total salivary pro-
tein reverted to nonnal values. 
The Role of Bacteria in Gingivitis 
Withdrawal of tooth-brushing in healthy human experimental subjects re-
sults in the accumulation of microbial plaque on the teeth and the develop-
ment of gingivitis (Loe et al., 1965; Theilade et al., 1966). If the bac-
terial plaque is removed by scaling, root planing and gingival curettage, 
the gingivitis is reversible. It indicates that bacteria are casually re-
lated in gingivitis (Krygier et al., 1973). 
Listgarten (1976) in a study with the electron microscope found that 
in healthy gingival sulcus a thin microbial layer approximately 60 um thick 
adhered to the enamel surface of teeth. The cells were predominantly coc-
coid in shape with a majority exhibiting cell wall features compatible with 
those of Gram-positive microorganisms. 
According to Socransky (1977), healthy periodontal tissues appear to 
be associated with a scanty microbial flora that is located almost entirely 
supragingivally on the tooth surface. Microbial cell accumulations are 
usually 1 to 20 cells in thickness and are composed mainly of Gram-positive 
caecal fonns. 
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The microorganisms commonly encountered in such sites include Strep-
tococcus mitfs, Streptococcus sanguis, Staphylococcus epidennidis, Rothia 
dentocariosa, Actinomyces viscosus, Actimyces naeslundii and occasionally 
species of Neisseria and Veillonella (Listgarten, 1976; Listgarten et al., 
1975; Socransky et al., 1977; Slots, 1977). 
According to Slots (1979), a scant microbial flora dominated by Gram-
positive microorganisms (85%), usually Streptococcus and facultative Actin-
omyces species is found in the healthy gingival sulcus. 
In the gingivitis sites on teeth, Listgarten (1976) found that bac-
terial deposits appeared to be thicker than that found in the nonnal samples, 
about 0.4 mm in thickness. The bacterial samples comprised a wide variety 
of microorganisms, including coccoid as well as filamentous fonns, and those 
with Gram-positive and variety of Gram-negative cell wall patterns. Also, 
flagellated bacteria and spirochetes were not uncommon in gingivitis samples. 
According to Socransky (1977), in experimental gingivitis there is an 
increase in the total mass of plaque and cell layers which often extend to 
100 to 300 cells in thickness. There is an increase in proportions of mem-
bers of the genus Actinomyces. This group of microorganisms tends to be the 
dominant genus associated with supragingival plaque, frequently comprising 
50% or more of the isolates (Listgarten et al., 1975; Loesche and Syed, 1975; 
Syed et al., 1975). In long standing gingivitis, approximately 25% of the 
microbial flora may be Gram-negative, including species of Veillonella, Vibro 
(CampYlogacter) and Fusobacterium. The Gram-negative cells appear to be 
located primarily on the surface of the bacterial plaque in subgingival 
sites (Listgarten, 1976; van Palenstein Heldennan, 1975). 
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According to Slots {1979), the development of gingivitis is accom-
panied by a marked increased in the total number of Gram-negative micro-
organisms. Fusobacterium nucleatum, Bacteriodes melaninogenicus ~· inter-
medius, Haemophilus species, and other Gram-negative microorganisms com-
prised about 45% of the total gingivitis isolates. Streptococcus and facul-
tative and anaerobic Actinomyces species constituted the majority of the 
Gram-positive gingivitis isolates. 
According to Page and Schroeder {1981), gingivitis and periodontitis 
in man and other animals, without exception, is caused by bacteria. How-
ever, the mere presence of bacteria, even the presence of specific patho-
gens is insufficient. They emphasized that an interaction of bacteria with 
the host's response systems is essential of the disease is to become estab-
lished and progress. This indicates that a healthy gingiva is the result 
of an equilibrium between pathogenic factors from the gingival crevice flora 
and the natural defense of the adjacent tissues. If the nature of gingival 
crevice flora alters either by an increase in the number of organisms or by 
a shift to a more virulent bacterial population, the equilibrium might be 
broken and inflanmation and destruction of tissues will follow. 
Enzyme-linked Inmunosorbent Assay 
Antibodies and antigens labeled with fluorescent dyes or isotopes 
have been used extensively for inununodiagnosis over the past two decades. 
However, they do have some disadvantages. Inmunofluorescence, usually de-
pends on subjective assessment of the end result, is time-consuming and is 
not easily automated so it can be used for only small batches of tests. 
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Radioill1Tlunoassay is particularly suitable for large-scale operations but 
the short shelf-life of the reagents, the expensive equipment, and because 
it carries some risks, has tended to exclude radioill1Tlunoassay from many 
small laboratories. These considerations have led workers to search for 
alternative labels for antiboides or antigens {Boller et al., 1976; Voller 
et al., 1978). 
Enzyme labeled reactants are safe, have long shelf life and yield 
objective results with the same sensitivity as radioirnmunoassay, yet can 
be used with relatively cheap, simple equipment. According to Engvall et 
al. {1971), by using enzyme-linked irnmunosorbent assay {ELISA) 1 - 100 ng/ml 
of the antigen could be determined. 
The basic ELISA test depends on two assumptions: (1) that antigen or 
antibody can be attached to solid-phase support yet retain ill1Tlunological 
activity and (2) that either antigen or antibody can be linked to an enzyme 
and the complex to retain both immunological and enzymatic activity. Accord-
ing to Voller et al. {1976) the double antibody 11 sandwich 11 for detection of 
antigen and the indirect method for detection of antibody are the most use-
ful in practice. 
It is clear from the work of Cantarero et al. {1980), Fields, et al. 
{1983) and Kemeny et al. (1985) that inmobilization of proteins to plastic 
material is dependent on the nature of the protein and the conditions used 
for coating. Kemeny et al. (1985) found that prolonged incubation of the 
antibody with the plates resulted in an increased capacity for binding 
antigen. Also, the rate of antigen bound to the antibody-coated plates was 
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much faster than that for the antibody alone bound to the plates, and the 
amount of antigen bound to the antibody-coated plates did not increase 
after 1 hour. 
A serious problem limiting the measurement of specific antigen is the 
high non-specific antibody binding to the plates. Urbanek et al. (1985) 
found that the rate of antigen bound to antibody-coated plates showed down 
after 3 hours incubation while the non-specific binding increased progres-
sively with longer incubation. Also, the rate of this binding was higher 
at 37°C than 21°C or 4°C, but this was largely due to increased non-specific 
binding at this temperature. They suggested that the best separation of 
specific antibody binding from non-specific binding was to incubate the 
plates at 4°C. 
Thus, in this study we reduced the incubation time to 1 hour and re-
duced incubation temperatures to 4°C. Also, we used 0.1% bovine serum al-
bumin (BSA) and 1% nonnal rabbit serum (NRS) as blocking agent. Also, Tween-
20 was included in all washing steps to prevent unspecific binding. 
CHAPTER III 
MATERIAL AND METHOD 
Selection of Patients 
Ten adult clinical patients with gingivitis, three females and seven 
males, ranging in age from 20 to 31 were selected from the Department of 
Periodontics, School of Dentistry, Loyola University of Chicago, based on 
the following clinical criteria described by Listgarten in 1976: (1) Gin~i­
val Index (GI): 2 - 3 ; (2) Pocket depth less than 5 mm; (3) Absence of 
radiographic evidence of bone loss. In addition, a group of age and sex-
matched clinically normal control subjects with healthy gingiva (3 females 
and 7 males, ranging in age from 23 to 31) were selected from dental stu-
dents at the School of Dentistry, Loyola University of Chicago. 
None of the participants had received a prophylaxis within the last 
six months. They were not taking any medication and did not show any evi-
dence of systemic diseases or salivary gland diseases. The female partici-
pants were neither pregnant nor taking oral contraceptives. 
Pocket depth was measured to the closest millimeter by means of a 
standard periodontal probe. Bone loss was considered to be absent, meaning 
that the alveolar crest is within 2 mm of cementoenamel junction(CEJ). The 
severity of gingival inflammation was assessed by the criteria of the Gingi-
val Index of Loe and Silness (1963) as modified by Loe (1967). Four gingi-
val areas, buccal, lingual gingival margin and interdental papillae, of all 
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teeth were given a score from zero to three as follows: 
0: normal (absence of inflammation) 
1: mild inflammation (slight change in color, little change in 
texture, no bleeding on probing.) 
2. moderate inflammation (moderate glazing, redness, edema 
and/or hypertrophy, bleeding on probing.) 
3. severe inflammation (marked redness and edema, hypertrophy, 
spontaneous bleeding or ulceration.) 
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The scores from the four areas of the tooth were added and divided by four 
to give the GI for the tooth. Finally, by adding the indices for the teeth 
and dividing by the total number of teeth examined, the GI for the individual 
was obtained. 
Experimental Design 
This study was reviewed by the chairman of the Loyola University Medi-
ical Center Institutional Review Board for the Protection of Human Subjects 
(IRB) before commencement. At the baseline, after signing the consent form, 
participants were given a clinical examination, and provided saliva samples 
as subsequently described. 
Patients with gingivitis received the following treatment: oral hy-
giene instruction, scaling, root planing and gingival curettage. It took 
four appointments, with a one week interval, to complete the treatment pro-
cedures. Two weeks after the last appointment, the patients came back to 
clinics for re-examination. At this time, the baseline procedures were re-
peated. for the control group._five weeks after the initial appointment 
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the baseline procedures were repeated, and the study terminated. 
-
Each subject brushed with water to remove plaque and residual debris 
before saliva collection. All participants spit saliva actively into a 
funnel connected to a graduated centrifuge tube until 3 ml were obtained. 
The collected saliva were clarified immediately by centrifugation at 3,675 
rpm for ten minutes. 0.1% (about 3 mg) cetylpyridinium chloride (CPC) was 
added to supernate, and the aggregated material in the supernate was removed. 
The supernate samples were centrifuged at 3,675 rpm for ten minutes again. 
The salivary supernatant then were frozen and stored for further tests, as 
described by Olson et al. in 1985. 
Experimental Design 
At the baseline 









.lt {l week) 
appointment 2 J (1 week) 




(Clinical examination and saliva collection) 
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ELISA Procedures 
Quantitation of lactoferrin was perfonned by enzyme-linked inmunosor-
bent assay (ELISA) as described below (Dipaola and Mandel, 1980; Kemeny et 
al., 1985; Urbanek et al.,' 1985): 
1. Tissue culture plates (American Scientific Products 24 - 2 ml 
wells) were employed as solid phase. 
2. The wells were coated with specific antibody to lactoferrin by 
passive adsorption and run in triplicate. 2 ml of rabbit anti-
human lactoferrin (Pel-Freez Biological) at concentration of 
10 ug/ml in 0.05 M Na2co3 buffer (pH 9.6) were added to each 
well. 
3. The coated wells were incubated at 4°C for overnight. 
4. The wells were washed four times to remove unbound antibody 
with tris-buffered saline (TBS). 
5. The coated wells were then treated with 0.1% bovine serum albumin 
and 1% normal rabbit serum in 0.05 M TBS at room temperature for 
30 minutes. 
6. The wells were washed four times with TBS. 
7. 2 ml of lactoferrin, prepared from human standard serum 
(Calbiochem) at concentrations of 10.3 to 26.9 ng/ml in 0.05 M 
TBS were added to triplicate wells to establish a stand~rd curve. 
8. 2 ml of test saliva diluted 1:500 with 0.05 M TBS, pH 7.4 
were added to the remaining wells. 
9. The plates were incubated at 4°C for 1 hour. 
10. The wells were washed four times with TBS. 
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11. 2 ml of an enzyme-labeled preparation of the antibody, rabbit 
anti-human lactoferrin-alkaline phosphatase {Pel-Freez Biologi-
cal), diluted 1/200 with 0.05 M TBS and 0.2% BSA were added and 
incubated at 4°C for 1 hour. 
12. The wells were washed four times with TBS. 
13. 2 ml of p-nitrophenyl phosphate, substrate, were added to each 
well at the concentration of 1 mg/ml in 0.1 M Ethanolamine 
{2-Aminoethanol) pH 9.6 containing 10 mM MgC1 2. 
14. The wells were incubated at room temperature for 30 minutes. 
15. 0.2 ml of 1 N NaOH were added to stop the enzyme reaction. 
16. 150 ul solution from each well were transferred to Dynatech 
plates containing 96 wells. 
17. The optical density {OD) of each well was read with Minireader 
II {Dynatech) at 410 nm. 
18. The concentration of lactoferrin was determined by comparison 
with a standard curve. 
The ELISA procedures were performed twice, and the average concentra-
tion of each sample was obtained. The values were analysed by the two sam-
ple student t test in order to establish a statistically significant dif-




Gingival Index (GI): 
At the baseline, the gingival index for the experimental group was 1.8 
± 0.2. After the periodontal treatment, the GI was reduced to 1.2 ± 0.3 
(Table 1). This was significantly different at the level of 0.001 (Table 3). 
For the control group, at the baseline and at the reexamination, the GI were 
0.2 ± 0.1 and 0.2 ± 0.2 respectively (Table 2), and did not differ signifi-
cantly {Table 3). 
Probing Pocket Depth: 
At the baseline, the mean probing pocket depth was 2.5 ± 0.2 lll11 for the 
experimental group, and was 2.0 ± 0.2 mm for the control group {Table 4 and 
5). This was significantly different at the level of 0.001 {Table 6). At 
the reexamination, the mean probing pocket depth was 2.4 ± 0.2 mm for the 
experimental group, and 2.0 ± 0.2 mm for the control group {Table 4 and 5). 
This was significantly different at the level of 0.001 (Table 6). However, 
there was no significant difference between at the baseline and at the reex-
amination either in the experimental or control group (Table 6). 
Lactoferrin Concentrations 
The value for lactoferrin from unstimulated whole saliva from ten 
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patients with gingivitis and ten clinically normal individuals, as quanti-
tated by the double antibody sandwich ELISA technique, are shown in Table 
7 and Table 8. For the experimental group, at the baseline the mean value 
was 0.57 ± 0.08 mg%, after the periodontal treatment the mean value was 
0.58 ± 0.09 mg%. There was no significant difference. For the control 
group, at the baseline the mean value was 0.56 ± 0.21 mg%, at the reexamin-
ation the mean value was 0.55 ± 0.15 mg%. There was no significant differ-
ence. Also, no significant differences were found between the experimental 
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Gingival Index tor the Control Group 
At the At the 
Subjects baseline reexamination 
11 O.J O.J 
12 0.2 0.2 
1.3 O.J 0 .3 
14 0.2 0.2 
15 o.o o.o 
16 0.5 0.5 
17 O.J o.4 
18 0.2 0.1 
19 o.o o.o 
20 0.2 0.2 
Mean 0.2 0.2 
S.D. 0.1 0.2 
Experimental 
Control Gr. 
* N.S. = not 
Table J 
Gingival Index ( Mean .:t. S .D.), 
comparison be~ween two groups 
At the At the 
baseline reexamination 
Gr. 1.8 ±. 0.2 1.2 ± O.J 








Probing Pocket Depth {mm) for the Experimental Group 
At the At the 
Patients baseline reexamination 
1 2.4 2.2 
2 2.8 2.7 
3 2.6 2.6 
4 2.5 2.3 
5 2.6 2.2 
6 2.5 2.4 
7 2.6 2.5 
8 2.3 2.3 
9 2.7 2.6 
10 2.4 2.3 
Mean 2.5 2.4 
S.D. 0.2 0.2 
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Table S 
Probing Pocket Depth (mm) tor the Control Group 
At the At the 
Subjects baseline reexamination 
11 2.0 2.0 
12 1.9 1.9 
13 2.2 2.2 
14 2.1 2.1 
15 2.0 2.0 
16 2.2 2.2 
17 2.1 2.1 
18 2.0 2.0 
19 1.7 1.7 
20 2.2 2.2 
Mean 2.0 2.0 
S.D. 0.2 0.2 
Table 6 
Probing Pocket Depth (mean~ S.D., mm), 
comparison between two groups 
At the At the t p 
baseline reexamination 
Experimental. Gr. 2.5 ,!_ 0.2 2.4 :t 0.2 1.4J N.S.* 
O.OO N.S. Control Gr. 2.0 :!:. 0.2 2.0 :t. 0.2 
t 7.14 5.26 
p ~0.001 ...( 0 .001 




Lactoferrin Concent~ations (mg%) tor the Experimental Group 
At the At the 
Patients baseline reexamination 
1 0.51 0.46 
2 0.53 o.49 
J o.68 0.58 
4 0.69 0.54 
5 0.51 0.63 
6 0.53 0.77 
7 0.52 0.56 
8 o.68 0.58 
9 o.46 0.57 
10 0.59 o.64 
Mean 0.57 0.58 
S.D. 0.08 0.09 
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Table 8 
Lactoferrin Concentrations (mg%) for the Control Group 
At the At the 
Subjects baseline reexamination 
11 0.48 0.51 
12 o.49 o.48 
lJ o.42 O.J8 
14 o.46 o.47 
15 o.66 0.61 
16 0.50 0.58 
17 o.46 0.52 
18 o.44 o.48 
19 1.13 0.94 
20 0.52 o.48 
Mean 0.56 0.55 
s.n. 0.21 0.15 
Table 9 
Lactoterrin Concentrations (mean ±. S.D., ~), 
comparison between two groups 
At the At the t p 
baseline reexamination 
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Experimental Gr. 0.57 s. o.oa 0. 58 :t- 0. 09 0.28 N.S.* 
Control Gr. 0.56 :t 0.21 0.55 ± 0.15 0.125 N.S. 
t 0.14 o.6 
p N.S. N.S. 
* N.S. = not significantly different. 
CHAPTER V 
DISCUSSION 
In the present study gingival tissues were assessed for the degree of 
inflammation by the criteria of the Gingival Index System (Loe and Silness, 
1963; Loe, 1967). ·The criteria include gingival tissues pale pink in color, 
stippled in texture, firm in consistency, and in the absence of bleeding 
upon probing is considered clinically normal. This criteria received a Gin-
gival Index score of zero. Gingival tissues displaying mild inflammation, 
slight change in color, slight edema, no bleeding on probing, and received 
a Gingival Index score one. Gingival tissues displaying moderate inflamma-
tion, redness, edema and glazing, in the presence of bleeding upon probing, 
and received a Gingival Index score of two. Gingival tissues which displayed 
severe inflammation, ulceration, and tendency to spontaneous bleeding re-
ceived a Gingival Index score of three. 
All participants in the control group were considered to be clinically 
normal, while in the experimental group, the scores were changed from 1.8 at 
the baseline to 1.2 at the reexamination. This significant change was ap-
parently the result of the scaling, root planing, curettage and oral hygiene 
instruction as performed in the protocol. 
The experimental results reported in this study do show the presence 
of lactoferrin in the whole saliva of the patients with gingivitis and in 
clinically normal individuals as measured by the ELISA technique. 
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Double antibody sandwich ELISA technique indeed can measure the con-
tration of lactoferrin in the whole saliva. However, the procedures used 
in this study were modified by precipitation of salivary acid mucopolysac-
charides with cetylpyridinium chloride (CPC) in the saliva processing. CPC 
is a good fixative for acid mucopolysaccharides (Williams and Jackson, 
1956). Since 1 - 100 ng/ml of the antigen can be determined by ELISA (~ng­
vall et al., 1971), ELISA is a very sensitive and useful method to measure 
such small amount of lactoferrin in saliva. 
The levels of lactoferrin in the saliva of the patients with gingivi-
tis and individuals with clinically normal gingiva do not have significant 
differences as determined by ELISA method. This suggests that gingivitis 
does not change the host's response with respect to the lactoferrin level 
in saliva. After the patients with gingivitis in this study received scal-
ing, root planing, gingival curettage and oral hugiene instruction, the 
level of lactoferrin in their saliva did not change. This suggests that 
lactoferrin level in saliva does not respond to the treatment of gingivitis, 
even when there is a significant clinical improvement in the gingival in-
fla11111ation. 
Also, in this study, the probing pocket depth in gingivitis group was 
2.5 ± 0.2 11111, and 2.0 ± 0.2 11111 in control group (Table 4 and Table 5), it 
does not suggest a similar effect in chronic periodontitis. It is not known 
whether there is any change of the level of lactoferrin in the saliva in the 
patients with chronic periodontitis. In such cases it is observed that 
they show deeper probing pocket depth and more soft tissue and alveolar 
bone destruction. A study of salivary lactoferrin levels in patients with 
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chronic periodontitis in order to assess any relevance and in comparison to 
the findings-reported in this study should be done in the near future. 
A previous study by Masson et al. (1966) reported the lactoferrin 
values in stimulated parotid saliva as low as 0.2 to 0.3 mg% by the electro-
phoresis method. Brandtzaeg (1971) reported lactoferrin concentration in 
stimulated parotid saliva to be about 1 mg% and also noted that unstimu-
lated salivary samples exhibited higher values than stimulated samples. 
Tabak et al. (1978) used the rocket electrophoresis method and re-
ported a range of 0.5 to 2 mg% lactoferrin in parotid saliva in their con-
trol subjects. 
Dipaola and Mandel (1980) who also used the ELISA method reported the 
lactoferrin value 0.81 ± 0.36 mg% in the unstimulated parotid saliva and 
0.54 ± 0.26 mg% in the stimulated parotid saliva, in normal human subjects. 
In their study, the saliva samples were diluted 1:25. In our study the sali-
va samples were diluted 1:500, and indicates that our ELISA techniques is 
more sensitive than that reported by Dipaola and Mandel. This may be due to 
the use of different buffer solution, incubation time and incubation temper-
ature. 
The sources of lactoferrin in human mouth has not been determined. 
However, it could arise in part from disrupting polymorphonuclear leukocytes 
and, in part, from epithelial cells that synthesize lactoferrin in the major 
and minor salivary glands (Masson, 1968; Tabak et al., 1978). 
The majority of salivary leukocytes continuously migrate into the 
mouth through the gingival crevice (Wright, 1964; Schiott and Loe, 1970), 
and 97 - 99% of them are neutrophils (Attstrom, 1970; Raeste, 1972). The 
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lactoferrin concentrations found in the saliva of the patients with gingi-
vitis and clinically normal individuals appear to be the same in this study. 
This was unexpected as a three-fold increase in the number of leukocytes en-
tering the gingival crevice had been observed during the course of gingivi-
tis (Schiott and Loe, 1970; Attstrom and Egelberg, 1971). This increased 
supply of lactoferrin could be balanced by the increased flow rate of gingi-
val crevicular fluid in gingivitis (Attstrom and Egelberg, 1971; Alfano, 
1974). 
The saliva contains other antibacterial proteins. Lactoferrin and 
several other proteins in saliva have been identified as antibacterial a-
gents, including secretory Ig A, the lactoperoxidase-thiocyanate-hydrogen 
peroxide system, and lysozyme. The concentration of each of these antibac-
terial agents alone may not be sufficient to influence the oral flora. They 
may need to act synergistically to accomplish that task. Arnold et al. 
(1979) found that although there was no significant difference in the lacto-
ferrin values in saliva between the patients with inmune dysfunction and con-
trols, the salivary concentrations of lysozyme and lactoperoxidase tend to 
be elevated in the group of inmune deficient patients as compared to normal 
controls. 
There are apparently conflicting results in the measurements of sali-
vary and sulcus fluid concentrations of antibacterial proteins. Friedman 
et al. (1983) found that lactoferrin in the crevicular fluid from the normal 
group was significantly lower than those from gingivitis group (0.63 vs. 1.5 
ug/ul), but there was no differences in the lysozyme concentrations between 
these two groups. van Palerstein Helderman (1976) found that there were no 
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significant differences in lysozyme concentrations between normal subjects 
and those with gingivitis. 
Another important consideration in future studies of salivary anti-
bacterial proteins was that of Olson et al. (1985) who found that the sali-
va of smokers contained lower concentrations of lactoferrin and greater con-
centrations of thiocyanate than the saliva in non-smokers, and no differen-
ces in lysozyme concentrations between these two groups. 
It is uncertain at present whether the levels of the other antibac-
terial agents in saliva have been changed in the patients with gingivitis 
or chronic periodontitis. 
These observations may reflect differences in the methods used to 
measure such proteins or variabilities in the salivary secretions of such 
proteins in subjects with gingivitis and in smokers. The reasons for such 
differences remain to be explained. 
SUMMARY: 
CHAPTER VI 
SUMMARY AND CONCLUSION 
Ten adult clinical patients with gingivitis and ten clinically nonnal 
age- and sex-matched control subjects were selected for measuring the con-
centrations of lactoferrin in saliva by using an enzyme-linked inmunosorbent 
assay (ELISA) technique. At the baseline, all participants were given a 
clinical examination, and provided saliva samples. Patients with gingivitis 
then received the following treatment: oral hygiene instruction, scaling, 
root planing and gingival curettage. Approximately five weeks after the ini-
tial appointment, both patients with gingivitis and control subjects came back 
for reexamination. At this time, the baseline procedures were repeated, and 
the study tenninated. 
CONCLUSION: 
(1) The experimental results reported in this study do show the pre-
sence of lactoferrin in the whole saliva of patients with gingivitis and 
clinically nonnal individuals. 
(2) Double antibody sandwich ELISA technique is a very sensitive and 
useful method to determine the concentration of lactoferrin in saliva. 
(3) The levels of lactoferrin in the saliva of patients with gingivi-
tis and individuals with clinically nonnal gingiva do not have significant 
differences as detennined by ELISA technique. This suggests_that gingivitis 
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does not change the host's response with respect to the lactoferrin level 
in saliva. 
(4) After the patients with gingivitis in this study received scaling, 
root planing, gingival curettage and oral hygiene instruction, the level of 
lactoferrin in their saliva did not change. This suggests that lactoferrin 
level in saliva does not respond to the treatment of gingivitis, even though 
there is a significant clinical improvement in the gingival inflanmation. 
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